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CHAPTER ONE 
LITERATURE REVIEW 
Introduction 
 Clostridium difficile infection is one of the most common nosocomial infections 
[1], and C. difficile is one of the most commonly isolated causes of hospital acquired 
diarrhea [2].  Currently, between 15-23% of nosocomial diarrhea cases are caused by C. 
difficile [3]. Clostridium difficile is a Gram-positive, spore forming, rod shaped, 
obligately anaerobic bacterium.  C. difficile belongs to the family Clostridiaceae, in the 
class Clostridia, and of the phylum Firmicutes.  C. difficile is an opportunistic 
gastrointestinal pathogen.  While it is not part of the normal flora in adults, patients can 
be colonized with C. difficile upon antibiotic treatment.  Antimicrobial treatment results 
in the reduction of the commensal microbiota, allowing for the efficient colonization of 
pathogenic C. difficile.  As a result of the widespread usage of antibiotics, C. difficile is 
prevalent in hospitals worldwide.   C. difficile is acquired by the ingestion of spores.  
Spores are a highly resistant cell type that allows the bacteria to remain dormant and 
persist on several hospital surfaces, including hospital equipment and the hands of health 
care workers.  Spores are resistant to most decontamination methods, with the exception 
of diluted bleach used to clean hospital surfaces.  This makes decontamination efforts 
challenging for health care systems.  Once the spore is ingested, it passes through the 
stomach and germinates in the small intestine. The resulting vegetative bacteria then 
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efficiently colonize the colon.  After colonization, vegetative cells produce toxins that 
accumulate in the colon and cause epithelial damage, with disease symptoms ranging 
from mild diarrhea, to pseudomembranous colitis, and even death from multi organ 
failure [4, 5].  Patients can be treated successfully with antibiotics for Clostridium 
difficile infection (CDI).  However, an estimated 20% of patients develop recurrent 
infection [6, 7].   
 The interaction between host epithelium and the bacteria during C. difficile 
colonization is a critical step in creating infection, yet the mechanism of interaction is not 
understood.  It is also not known how C. difficile evades host immune responses.  These 
are important questions for clinicians and scientists to answer in advancing treatment and 
prevention of CDI. 
  Bacterial biofilms have been identified in several human diseases.  Biofilms can 
facilitate attachment to host mucosa, and can protect bacteria from critical host defense 
molecules like antibodies and anti-microbial peptides.  Additionally, biofilms can help 
bacteria avoid host immune recognition and persist in the host [8].  A C. difficile biofilm 
could promote persistence and relapse (a recurrence with the same strain) if it serves as a 
reservoir for spores.   
 I have sought to characterize a previously unidentified C. difficile biofilm. C. 
difficile biofilms could contribute to CDI by facilitating attachment of C. difficile to host 
epithelium; by resisting host defenses and antimicrobial drugs; by accumulating toxin and 
directing it to host tissues; and by harboring dormant spores that could facilitate recurrent 
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disease.  Understanding how C. difficile interacts with host tissues, and evades host 
defenses and therapeutics, would greatly facilitate development of novel treatments. 
Epidemiology of CDI 
Disease Characteristics and Epidemiology 
 The earliest indication of CDI includes symptoms of diarrhea, fever, and bloating.  
The toxins damage the gut mucosa, which creates an inflammatory response.  If the 
infection continues, CDI can become more severe with the formation of a 
pseudomembrane.  A pseudomembrane is made up of dead epithelia, sloughed-off 
mucous, leukocytes, and fibrin which forms over the inner surface of the colon [8].  
Finally, toxic megacolon can occur in which the colon becomes distended and bloated 
with gas and the colon becomes paralyzed with the possibility of rupture.  Kidney failure 
can occur, as well as heart damage, from the systemic spread of toxin.  Large sections of 
colon may need surgical removal, and if left untreated, any of the severe symptoms can 
result in death.   
 The rates of CDI are increasing worldwide, in both the number of infected 
patients and in mortality.  In the USA in 1996, the number of reported CDI cases was 
82,000. By 2003, the rate had doubled [9].  The mortality rate also increased. One study 
indicates that between 1999-2004 the mortality rate has increased 35% each year [10].  
These increases are primarily attributed to the emergence of hypervirulent strains that 
have greater antibiotic resistance than previous epidemic strains.   
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Treatment and Prevention 
 The widespread use of antibiotics has caused C. difficile to be endemic in 
hospitals worldwide.  Use of nearly any antibiotic will compromise the gastrointestinal 
microbiota, and can make a patient susceptible.  Several antibiotics can place a patient at 
greater risk for CDI than others, including cephalosporins and ampicillin [11, 12].  C. 
difficile has developed resistance to some antibiotics, most notably the third generation 
cephalosporins, clindamycin, and recently the floroquinolone class [11-13].  One study 
indicates that fluoroquinolones were responsible for 55% of infections during the 
hypervirulent C. difficile outbreak in Quebec in the mid-2000’s [14].  As these antibiotics 
are widely used, the most prevalent epidemic C. difficile strains are often resistant to 
these common antibiotics.  Vancomycin and metronidazole are effective antibiotics 
currently in use to treat CDI, and presently there has not emerged any resistant C. difficile 
strains to either antimicrobial [8].  However, treatment with metronidazole has required 
an increase in the dosages for effective treatment of symptoms [15].   
 The costs associated with CDI are great.  CDI prolongs a patient’s hospital stay, 
treatments are extended, and a recent estimate placed the cost of CDI for each case can 
add up to $4000 to a U.S. patient’s hospital bill.  This estimate can increase up to $18,000 
for recurrent CDI [5, 16].  With the onset of recent epidemics, the current estimate for 
U.S. healthcare systems places the annual cost of CDI treatment to be $3.2 billion [17]. 
 To acquire CDI, a susceptible patient must ingest C. difficile spores, which are 
widespread in hospital environments.  Spores can be found on hospital surfaces, medical 
devices, and the hands of healthcare workers [5].  C. difficile spores can remain on 
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hospital surfaces for extended periods of time, in one estimate as much as 7 months [18] 
Therefore, it is understandable that aggressive decontamination methods for C. difficile 
spores are a main priority for hospitals.  C. difficile spores are highly resistant to many 
decontamination methods.  Most importantly, antibacterial alcohol-based hand gels are 
not effective in killing C. difficile spores [19].  With the widespread use of hand gels that 
can often be used in lieu of traditional soap and water hand washing methods, there is 
evidence that the recent rise in CDI can be partially attributed to hand gel use [20]. 
Proper hand washing methods have been encouraged, along with the use of gloves to 
reduce the incidence of transmission from health care workers to patients [21, 22].  
Additionally, the use of bleach to clean surfaces and using disposable medical equipment 
has been shown to reduce rates of transmission [21].   
 Finally, limiting the use of antibiotics can be effective in preventing CDI 
acquisition.  A recent study with hypervirulent C. difficile using a comprehensive 
approach to reduce epidemics showed that increased hygiene and cleaning measures, 
along with controlled and limited antibiotic usage can reduce the CDI incidence rate by 
as much as 78% [23].  Limited usage of cephalosporins, clindamycin, macrolides and 
ciprofloxacin with a hypervirulent C. difficile outbreak in Quebec reduced the total 
number of CDI cases by 60% [24].   
Recurrence of Disease  
 Most patients are successfully treated with antibiotics, which clears the infection 
and eradicates disease symptoms.  However, the antibiotic therapies used do not always 
eradicate the organism.  In 20-35% of CDI cases, the disease returns even though the 
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initial symptoms have been treated [7].  Disease recurrence usually occurs within 3-30 
days after the completion of antibiotic treatment [6].  Disease recurrence can be due to 
either relapse with the same strain of C. difficile, or reinfection with a new strain.  The 
time for relapse with the same strain in general is much shorter than reinfection with a 
new strain [6].  One study indicates the mean time for relapse is 14.5 days, with 42.5 days 
being the mean time to reinfection [25].   There are several potential explanations 
pertaining to the mechanism of recurrent infections, including inadequate immune 
responses, and persistent disruption of the microbiota [26-29].  One study suggests that 
the diversity of the microbiota in recurrent CDI patients is significantly reduced 
compared to healthy individuals, indicating that the microbiota has not adequately 
regenerated to exclude future colonization with toxigenic C. difficile [26].  While these 
are likely contributing factors to recurrence, there are quite possibly other unknown 
mechanisms that contribute to the frustrating issue of recurrent CDI. 
Sporulation 
 Spores are a highly resistant, metabolically inactive dormant cell type.  C. difficile  
spores are resistant to heat, chemical and pH extremes, mechanical forces, and aerobic 
environments.  Spores persist on hospital surfaces and, once ingested, spores are resistant 
to destruction by stomach acid, and travel to the small intestine for germination.  The 
ability of spores to persist in the environment is a key factor in CDI acquisition and 
transmission [52].   
 The process of sporulation creates a resistant spore from a vegetative cell.  This 
complex process is highly regulated by a sophisticated gene expression network.  A 
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signaling cascade of sigma factors creates a stepwise response to several signals that can 
induce sporulation to begin.  The most common signal that can initiate sporulation is 
starvation.  In the case of C. difficile, an obligate anaerobe, oxygen can initiate 
sporulation as well.  Little is known about the signaling network in C. difficile.  However, 
the molecular mechanisms are better understood in B. subtilis.   
 Spo0A is a master regulator, and is phosphorylated by a phospho-relay cascade, 
leading to the activation of Spo0A.  Spo0A~P can then activate downstream regulators 
which initiate steps to sporulation, and repress vegetative cell functions [30].  A sigma 
factor cascade is the major controller of sporulation, which occurs in both the mother cell 
and the spore.  Spo0A~P and sigma H are activated in the pre-divisional cell, which leads 
to an asymmetric division creating the prespore and the mother cell divided by a septum 
[30].  Sigma F is then activated in the prespore, while sigma E is activated in the mother 
cell.  Sigma E leads to the production of coat proteins and, by communication with the 
forespore, activates Sigma G in the forespore. Sigma G initiates a signaling cascade that 
results in the activation of sigma K, leading to the assembly of the outer spore coat [30].   
 In the initial stages of sporulation, asymmetric division occurs two z rings at 
either pole of the sporangium.  One z ring forms the septum, while the other z ring is 
disassembled.  During the septum formation, the chromosomes replicate and form an 
axial filament. The remaining section of the chromosome is actively transported into the 
forespore and segregated from the mother cell with the completion of the septum.  This 
results in two distinct cells, both with a complete chromosome.  Then, the mother cell 
migrates around the forespore and pinches the membrane off to completely engulf the 
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forespore.  At this point, the chromosome in the forespore is remodeled into a circular 
structure, the cortex forms a thick layer of cell wall material and, finally, the protective 
protein spore coat forms around the outside, completing the synthesis of the spore.  Then, 
the mother cell lyses by the action of lytic enzymes and liberates the mature spore [31].  
Pathogenesis 
 Toxins and Other Virulence Factors 
 Clostridium difficile produces two large toxins, A and B, encoded by tcdA and 
tcdB, respectively.  Initially, toxin A was believed to be the most important virulence 
factor, when the work of Lyerly and Wilkins determined that Toxin A given 
intragastrically produced similar disease symptoms to a total supernatant, while toxin B 
did not produce significant disease.  Toxin B was only effective as a cytotoxin when 
given to animals with bruised ceca, or given with small amounts of toxin A [32]. The 
view that toxin A was the important virulence factor was challenged when clinical reports 
provided evidence of disease causing strains that did not produce toxin A.  Strain 8864 is 
a naturally occurring toxin A-, toxin B+ strain capable of producing infection [33].  
Additional A-/B+ strains were later reported that were responsible for fatal human cases 
and epidemics, as well as producing disease in hamsters [34-36].  Genetic manipulation 
of C. difficile has allowed for molecular analysis of the importance of toxins A and B as 
virulence factors.  By constructing isogenic mutants of tcdA and tcdB in strain 630, 
followed by introduction of the mutant strain to a hamster model, it was shown that toxin 
B is the essential virulence factor [37].  Hamsters infected with the toxin B mutant 
displayed significantly less mortality than either the wild type or toxin A mutant.  The 
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fatal cases of hamsters infected with toxin B mutants were found to have revertant strains 
in which the recombination vector was excised, providing additional support that toxin B 
production is favored for pathogenesis [37].  A more recent study determined that both 
toxins contribute to virulence in a hamster model.  Null mutations in tcdA and tcdB were 
followed with infection in the master model.  Hamsters infected with C. difficile without 
toxin B (A+, B-) survived several days longer than those infected with C. difficile lacking 
toxin A (A-, B+) [38].  It appears that both toxins contribute to pathogenesis, though 
toxin B makes a larger contribution to virulence.  It is likely though that the contribution 
of toxins to virulence is not yet fully understood.  
 The Pathogenicity Locus or PaLoc encodes the genes for toxin A and B, tcdA and 
tcdB, as well as three other genes tcdR, tcdE, and tcdC [39].  Non-toxigenic strains lack 
the PaLoc entirely [40].  Toxin A and B are large toxins that belong to the family of 
Large Clostridial toxins, which includes other toxins from C. sordelli and C. novyii, all of 
which share similar 3-domain structure and mechanism of action [41].  In C. difficile 
strain VPI 10463, tcdA is an 8133 base pair gene, encoding a 2710 amino acid, 308 kDa 
protein.  tcdB is 7098 nucleotides, encoding a 3266 amino acid, 279 kDa TcdB protein 
[42, 43]. 
 The three other genes encoded in the locus include tcdC, tcdE, and tcdR [39].  
tcdC encodes a 26 kDA protein that is thought to act as a negative regulator for toxin 
production by acting as an anti-sigma factor [44].  tcdE encodes a protein with unknown 
function, but shares homology with phage holins.  TcdE protein has been shown to play a 
role in toxin release during stationary phase [45].  tcdR codes for a sigma factor and is 
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required for tcdA and tcdB expression, acting as a positive regulator [46, 47].  TcdR is a 
22 kDa protein sigma factor, which binds to RNA polymerase core enzyme and allows 
transcription at specific promoters.   
 Separate from the PaLoc, C. difficile encodes an additional toxin called binary 
toxin.  Binary toxin is produced in two individual fragments, CdtA and CdtB, which are 
secreted separately and join extracellularly to form a functional toxin.  CdtA is the 
enzymatic fragment, while CdtB is responsible for binding and translocation [48].  Host 
cells take up binary toxin through receptor-mediated endocytosis.  Once inside the cell, 
binary toxin ADP-ribosylates toxin, which leads to the degradation of the cytoskeleton 
[49].  Binary toxin is not present in all C. difficile strains, and it has been found in strains 
that do not contain the PaLoc.  Strains that contain the binary toxin without toxins A and 
B are able to colonize animals, but do not create any disease symptoms.  In the ligated 
ileal loop assay, however, fluid accumulation can be caused by purified binary toxin [50, 
51].   
 In addition to the toxins produced by C. difficile, there are several other virulence 
factors including the bacterial capsule, fimbriae, and hydrolytic enzymes.  These 
virulence factors have been shown to be present more frequently in highly toxigenic 
strains [52, 53]. 
 Mechanisms of Host Response and Pathophysiology 
 Following secretion from the bacteria, toxins A and B bind to the host cell 
surface.  Once bound, the toxins are endocytosed via clathrin-mediated endocytosis.  
During cellular uptake, the toxins are proteolytically processed.  The toxins contain both 
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enzymatic and translocation domains.  The C terminus contains the translocation domain 
and remains in the endosome after endocytosis, while the enzymatic domain is delivered 
into the cytoplasm [54].  Autocatalytic cleavage of toxin B is carried out by a cysteine 
protease, which activates toxin B in the cytoplasm [55].  Once inside the cytoplasm, toxin 
A and B can glucosylate GTPases.  The GTPases are signaling proteins that cycle 
between an active and inactive state.  When bound with GTP, the GTPase is active and 
can interact with numerous effector molecules.  GTP hydrolysis to GDP results in the 
inactivation of the GTPase [56].  When the toxins glucosylate the GTPase, the protein is 
permanently inactivated.  This blocks the action of GEF and GAP proteins preventing 
any new GTP exchange, and ultimately blocking the interaction with effectors [57].  The 
inactivated GTPases affect the host cell cytoskeleton causing cell rounding and inducing 
apoptosis [7, 58].  In addition to GTPase activity, toxin A and B can damage the 
mitochondria, which can lead to apoptosis [59], and disrupt the tight junctions in the gut 
epithelia [60].   
 Spore Germination, Colonization and Adherence 
 CDI occurs when antimicrobial-treated patients ingest C. difficile spores, spores 
germinate in the small intestine, and the resulting vegetative cells colonize the colon. The 
vegetative cells produce toxin, which damages the mucosal and epithelial cell surfaces 
and creates symptoms of infection.  C. difficile spores do not create toxins on their own, 
and are metabolically inactive.  Therefore, C. difficile spores are incapable of producing 
infection without germination.  Spore germination occurs when spores undergo a 
complex process to resume metabolic activity and growth, resulting in vegetative cell 
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growth.  The process of spore germination in C. difficile is not well characterized.  In 
general, spores begin to germinate in response to environmental conditions that indicate a 
favorable environment for vegetative cell growth.  In B. subtilis, germination begins in 
response to several germinants, including the nutrient glucose.  When glucose binds 
receptors in the inner membranes of the spore, this interaction triggers the release of 
cations and dipicolinic acids, leading to an influx of water to rehydrate and expand the 
spore core.  This is followed by the hydrolysis of the cortex peptidoglycan and 
germination is complete when the spore resumes full metabolic activity and outgrowth 
[61].   
 While C. difficile spore germination is not well understood, it has been noted that 
a common bile acid, taurocholate, activates germination in C. difficile spores [62]. 
Taurocholate is hydrolyzed by the action of other bacteria that are normally present in the 
microbiota, which breaks taurocholate into secondary bile salts cholate and 
chenodeoxycholate [63, 64].   These secondary bile salts have been shown to inhibit C. 
difficile germination, which may explain the contribution of the microbiota in preventing 
C. difficile colonization [63].   
 Colon colonization is a key event in the course of CDI.  After a patient ingests 
spores, C. difficile must colonize the gut to produce high quantities of toxins, which 
create symptoms and colonic tissue damage during CDI.  Colonization can occur with 
both toxigenic and non-toxigenic strains.  Interestingly, early work by KH Wilson 
indicated that colonization of animals with non-toxigenic strains of C. difficile can 
prevent colonization with toxigenic strains and development of disease [62].  This 
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indicates that competition for colonization is an important factor in CDI.  As referenced 
earlier, the normal gastrointestinal microbiota, when present in a healthy individual, 
excludes C. difficile from the gastrointestinal tract and results in protection from CDI.  
Further studies from Dr. Dale Gerding’s laboratory indicate that colonization with non-
toxigenic C. difficile is effective as a preventative treatment for CDI with a toxigenic 
strain in both humans and hamsters [65].   
 For colonization to occur, the bacteria must associate with the mucosal 
epithelium.  Unfortunately, relatively little is known about the interaction of C. difficile 
with the gut.   During infection, the colonic mucosa is shed from the epithelial surface.  
Additionally, the flow of luminal contents in the colon creates an environment with 
considerable mechanic force.  Yet, despite these physical stresses C. difficile is able to 
persist and remain in the gut.  Clearly the adhesion of C. difficile to the gut is a strong and 
resistant interaction.   
 Several adhesins have been identified in C. difficile.  Surface layer protein SlpA is 
from a protein class of S-layer proteins that are secreted in many bacterial species [66].  
After secretion, S-layer proteins self assemble into a lattice on the cell surface and 
provide structural integrity.  In addition to its role in cell structure, S-layer proteins have 
been implicated in immune evasion and adhesion [67].  S-layer proteins are 
glycoproteins, and glycosylation on the bacterial surface has been shown to block 
complement-mediated lysis enabling immune system evasion [68].    
 Cwp66 is a surface-associated adhesin, and is described as a heat shock protein 
located on the bacterial surface [69] .  Additional adhesins that have been identified in C. 
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difficile include the flagellin FliC and the flagellar cap FliD [70], the heat-shock protein 
GroEL [71], and fibronectin-binding protein Fbp68 [72].    
Biofilm Structure and Components 
 Biofilms are organized bacterial 3-dimensional communities surrounded and 
embedded in an extracellular matrix [73].  Biofilms are ubiquitous in nature, and are 
prevalent in natural,  industrial, and hospital settings [74].  Traditionally, it has been 
understood that biofilms must attach to a surface, either living or non-living, though it has 
now been determined that biofilms may not always be attached to a surface in the human 
host, as has been demonstrated in P. aeruginosa and S. aureus [75-77].  The cells in a 
biofilm are distinct from planktonic cells of the same organism.   Bacteria in biofilms 
exhibit community behavior and specialized functionality [78], creating a functionally 
heterogeneous community [74].  Large gene loci have been found to regulate biofilm 
formation and regulation [79].  When a cell switches to a biofilm mode of growth, 
changes in gene expression lead to varying phenotypes.  Cellular specialization and 
heterogeneous cell populations will be discussed further with regard to Bacillus subtilis 
biofilms. 
 The first step in biofilm formation is the attachment of planktonic cells to a 
surface, creating a small microcolony.  Cell-cell communication in this small 
microcolony is accomplished through quorum sensing (QS), which allows bacteria to 
survey and sense population density through a series of secreted signals and receptors.  
With QS, bacterial cells are able to coordinate behavior and respond to environmental 
factors as a community [74,81].  The initial microcolony then expands through 
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recruitment of additional planktonic cells and cellular division, while an extracellular 
matrix develops to encase the bacteria.  The biofilm is composed of cells and a 
surrounding self-produced extracellular matrix that covers and protects the bacteria.  The 
extracellular matrix is typically composed of three primary components, including 
protein, nucleic acid, and polysaccharides, and is often referred to as the extracellular 
polymeric substance (EPS).  The extracellular matrix can facilitate extracellular signaling 
and cell-cell communication.  Biofilms are porous, and some biofilms contain channels 
that aid in nutrient and signaling distribution [73, 74, 80, 81].  The final step in biofilm 
development is dispersion.  Motile cells disperse from the mature biofilm which allows 
bacteria to colonize new surfaces.  Erosion of the biofilm refers to continuous release of 
single cells or small clusters over an extended period.  Sloughing dispersal liberates large 
portions of the biofilm late in biofilm development.  Finally, seeding dispersal is a rapid 
method of dispersal to release single cells or small clusters in a shortened time period 
[82].  Dispersal can be accomplished through the production of several matrix-degrading 
enzymes, including proteases, deoxyribonucleases, and glycosidases [82].  Both nitric 
oxide and D-amino acids have been demonstrated to facilitate dispersal from the B. 
subtilis biofilm [83, 84].   
 Biofilms have been implicated in numerous human infections, and biofilms 
contribute to survival in a variety of ways.  Biofilms help bacteria avoid phagocytosis, 
exclude host defense molecules like antibodies and anti-microbial peptides, adhere to 
epithelial tissues, and resist antibiotics [85, 86].  Antibiotic resistance can be increased in 
some cases up to a thousandfold-greater than planktonic cells [87].    
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Biofilms in Human Disease 
 Biofilms are found in many niches in the mammalian host, including the surface 
of the gut mucosa [88-90].  Biofilms have now been recognized as the cause or as an 
exacerbation of numerous chronic infections, including periodontitis, device-related 
infections,  CF pneumonia, chronic urinary tract infections, recurrent tonsillitis, chronic 
rhinosinusitis, chronic otitis media, and chronic wound infections  [85].  Hall-Stoodley 
and Stoodley suggest that biofilm development is a “persistence factor” rather than a 
virulence factor.  Biofilms are found during infection, but also can be found in control 
specimens without infection, as seen in the case of chronic rhinosinusitis [85].  
Additionally, patients with biofilm infections will often exhibit signs and symptoms of 
infection, yet diagnostic attempts at culture are negative.  Culture tests and detection of P. 
aeruginosa by FISH in chronic wounds showed no correlation with infection, despite 
demonstrated biofilms present in the wound [91].  Due to the difficulty associated with 
diagnosing biofilm infections, efforts have been made to outline criteria for chronic 
biofilm infections.  Parsek and Singh in 2003 proposed 4 diagnostic criteria; 1) surface 
associated, 2) cell clusters encased in matrix, 3) localized infection, 4) antibiotic resistant 
[86].  These criteria were followed in 2009 by Hall-Stoodley and Stoodley with 2 
additional diagnostic postulates to include 5) culture-negative result, and 6) ineffective 
host clearance [85].   
 Due to enhanced antibiotic resistance and evasion of host defenses, biofilm 
infections can be difficult to treat.  Several studies describe biofilm matrix and dead cells 
as a mechanism for delayed antibiotic delivery and “dilution” of antibiotics to live cells in 
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the biofilm [92].  Jefferson et al. described a delay in antibiotic penetration of the biofilm 
matrix.  While the extracellular matrix does not inhibit the penetration of antibiotics into 
the biofilm, the rate of penetration may be slowed enough to allow biofilm cells to 
express particular resistance genes [93].  Biofilms often exhibit resistance to host defense 
mechanisms in addition to antibiotics.  Lam and Costerton demonstrated biofilm growth 
in post-mortem lung tissue from P. aeruginosa-infected cystic fibrosis patients.  The lung 
tissue showed that biofilm was surrounded, but not penetrated, by antibodies and 
inflammatory cells [94].  A 1997 study also demonstrated that IgG was bound to the 
surface of biofilms, yet the antibody failed to penetrate the EPS [95].  Resistance to 
phagocytosis by the action of the extracellular matrix has been documented in P. 
aeruginosa and S. aureus [96, 97].   
Bacillus subtilis Biofilm 
 Bacillus subtilis is a Gram-positive, rod-shaped, aerobic, spore-forming bacterium 
that is commonly found in the soil.  B. subtilis is not typically classified as a pathogenic 
bacterium, though it can cause disease in immunocompromised patients [98].   It is 
frequently used as a probiotic supplement.  B. subtilis is a model organism for Gram-
positive sporulation and biofilm growth, and is commonly used in laboratories for genetic 
research as it is highly responsive to genetic manipulation.  The Bacillus subtilis biofilm 
has been well characterized and is the best studied Gram-positive biofilm.  For this 
reason, we base several of our experimental questions from characteristics seen in B. 
subtilis biofilm development, conscious of the reality that B. subtilis and C. difficile are 
quite different.  
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 Wild type (WT) strains of Bacillus subtilis form a biofilm, or pellicle, in standing 
liquid culture at the air-liquid interface.  The WT biofilm displays a structurally complex 
morphology, with aerial projections serving as the preferential site of sporulation [99].  B. 
subtilis biofilms exhibit cellular differentiation through the formation of a heterogeneous 
cell population.  Individual cells in the biofilm exhibit specialized behavior.  Initially, 
biofilm development begins with the aggregation of motile, swimming cells to the air 
liquid interface.  From there, cells adhere to one another and cellular division results in 
long, ordered chains of cells within 12-24 hours of culture incubation.  Biofilm formation 
is controlled by the master regulator Spo0A.  Spo0A is activated by phosphorylation in 
response to nutrient limitation and regulates both matrix production and sporulation [100, 
101].  Once cells have reached stationary phase, cellular signaling begins, which initiates 
matrix production.  At about 48 hours of growth, the level of Spo0A~P is at a low 
concentration to permit cells to differentiate from motile cells to matrix 
producers/cannibal cells [78, 102].  Spo0A~P regulates several genes responsible for 
matrix production, notably eps and  tasA.  TasA is a major structural protein component 
of the BS biofilm, and eps is responsible for the polysaccharide component of the 
extracellular matrix [103].  Two other regulators are also involved in cellular 
differentiation during this stage of biofilm development.  DegU is a protein regulator 
responsible for the production of miner cells.  These cells produce exoproteases that 
degrade extracellular proteins, resulting in amino acid availability for the cells.  This 
delays nutrient limitation and thus sporulation.  Another regulator, ComA, allows for the 
specialization of surfactin producers and competent cells [104].  Matrix production is 
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thought to be a metabolically taxing event during biofilm formation.  This metabolic 
strain creates distinct regions of the biofilm with severe nutrient limitation.  Nutrient 
limitation initiates additional signaling cascades resulting in high levels of Spo0A~P, 
leading to sporulation [78, 104].  By 72 hours of growth, the majority of cells in the 
biofilm have specialized from matrix-producing cells to sporulating cells [78].   For a 
detailed review of sporulation in B. subtilis please refer to page 7-8.  The study of cell 
specialization and cellular fate in the B. subtilis biofilm has led to a model of natural 
sporulation not previously identified.  Previous studies had not outlined biofilm growth as 
a step in sporulation.  Laboratory studies detailed the steps of sporulation from liquid 
growth, which may not be representative of what is occurring in nature.  We are 
particularly interested in the cellular fate of the B. subtilis biofilm in comparison with the 
C. difficile biofilm, in which I will propose a unique model for cell fate in Gram-positive 
biofilms.   
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CHAPTER TWO 
MATERIALS AND METHODS 
C. difficile strains  
 Seven human clinical isolates of C. difficile were chosen for study.  All strains 
were obtained from the culture collection of Dr. Dale Gerding.  Two toxigenic strains, 
BI6 and BI17, are part of the BI genetic group and have been classified as hypervirulent 
[13] .  Two additional toxigenic strains were chosen including J9 and K14, known to 
cause disease but not classified as hypervirulent.  Strains M3, BY1, and CH1 are non-
toxigenic. 
Biofilm Culture Conditions 
 All C. difficile strains were grown under anaerobic conditions (85% N2, 5% H2, 
and 10% CO2) in a Bactron IV chamber (Sheldon Manufacturing, Cornelius, OR) at 
36°C.  Overnight cultures were grown in Tryptic Soy (Tsoy) broth (BD Biosciences, 
Boston, MA) until an O.D. of 0.8.  1ml of culture was then centrifuged and resuspended 
in 2ml of Tsoy broth.  Black polycarbonate membranes (Catalog # HTBP02500 
Millipore, Billerica, MA) were inoculated with 10 μl resuspended culture.  The 
polycarbonate membranes were placed on Tsoy agar nutrient medium and incubated for 
1-14 days at 37° C.   
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Visualization of Biofilm Architecture   
 Biofilms were cultured as described above.  The polycarbonate filter is transferred 
to a glass slide.  To preserve colony architecture, 1% gluteraldehyde was carefully 
pipetted onto the biofilm and incubated for 30 minutes.  Biofilms were then stained with 
0.05% calcofluor white in 1M Tris, pH 9 for 15 minutes, followed by rinsing with 
deionized water. Biofilms were then imaged using a confocal laser scanning microscopy, 
LSM 510 (Carl Zeiss Inc, NY, USA) using Diode laser (405-430nm). Confocal images 
were analyzed using Zeiss LSM Image Browser software. 
Matrix protein Isolation 
 Biofilms were cultured as described above.  The biofilm was scraped from the 
polycarbonate membrane and suspended in 0.5 ml 0.9% NaCl.  Bacteria were separated 
from the matrix fraction by centrifugation (14,000 rpm for 20 minutes at 4°C) and 
filtration of the supernatant through 0.22um PVDF membrane filters (Millipore, Billerica, 
MA).  For SDS-PAGE, the filtered supernatant was incubated with 1/100 volume 2% 
deoxycholate for 30 min at room temperature, then 1/10 volume of 100% trichloroacetic 
acid was added and the mixture incubated for 2 hours on ice.  The pellet was centrifuged, 
washed with 500 μl cold 100% acetone, and sat for 10 minutes to dry, then resuspended 
in 50 μl MQ-H2O.  Then, 12.5 μl 4x SDS-PAGE protein loading buffer was added for 
SDS-PAGE electrophoresis. Proteins were visualized using Coomassie Blue stain 
(Biorad, Hercules, CA). 
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Total soluble protein Isolation 
 Biofilms were cultured as explained previously.  The biofilm is scraped from the 
polycarbonate membrane and suspended in 0.5 ml 0.9% NaCl.  Bacteria were separated 
from the matrix fraction by centrifugation (5,000 rpm for 20 minutes at 4°C).  The matrix 
supernatant was removed, and the cell pellet was resuspended in 0.5 ml 0.9% NaCl.  The 
cells were again centrifuged (5,000 rpm for 20 minutes at 4°C) and the supernatant 
removed to wash the cells for a total of two washes.  The biofilm cells were then 
resuspended for a third time in 0.9% NaCl.  Cells were sonicated (Branson 450 Sonifier, 
Danbury, CT) on ice for 5 minutes total with 1 minute bursts (output control 5).  After 
sonication, the cells were centrifuged at 14000 rpm for 30 minutes at 4°C.  The 
supernatant was removed and 100 μl 4x SDS-PAGE running buffer added and boiled for 
5 minutes.  The lysed cells were electrophoresed through a 12% SDS-PAGE and proteins 
were visualized using Coomassie Brilliant Blue stain. 
Proteomic Identification of C. difficile Matrix Proteins 
 Matrix protein extracts were electrophoresed using denaturing 12% SDS-PAGE 
and stained with Coomassie Brilliant Blue.  We identified 4 abundant matrix protein 
bands which were distinct from a comparative SDS-PAGE gel of C. difficile surface 
protein bands.  The 4 bands were excised, and the proteins were identified using MALDI-
TOF-TOF mass spectrometry analysis.  All mass spectrometry analyses were performed 
by Alphalyse Inc, Palto Alto, CA. 
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Phenol Sulfuric Acid Assay 
 Three standard concentrations of galactose were made by diluting galactose in 
MQ-H2O, 50 μg/ml, 250 μg/ml, and 500 μg/ml.  Matrix extracts were made as previously 
described using biofilms of three differing ages (1, 3, and 6 days).  0.5 ml of non-
precipitated matrix suspended in 0.5 ml 0.9% NaCl, or 0.5 ml galactose standard, or 0.5 
ml MQ-H2O, was combined in a glass tube with 0.5 ml 5% phenol in 0.1M HCl and 2.5 
ml H2SO4, and allowed to incubate for 5 minutes for color development. After 
incubation, the color of each matrix sample was then visually compared with the 
standards.   A darker shade (range from clear to scarlet red) indicates a higher 
polysaccharide concentration. 
Polysaccharide staining and Microscopy 
 Concanavalin A (ConA) lectin conjugated with Texas Red (Molecular Probes, 
Eugene, OR) was used to label extracellular polysaccharides. Stock solutions were 
prepared according manufacturer’s instructions and stored at -20C in 100 μl aliquots. 
Con A was diluted in PBS before use to a lectin concentration 100 μg/ml.  Wheat Germ 
Agglutinin (WGA) (Molecular Probes, Eugene, OR) was made to stock solutions 
according to manufacturer’s instructions and stored at -20°C in 100 μl aliquots.  WGA 
was diluted in PBS before use to 3 lectin concentrations of 10 μg/ml, 50 μg/ml, and 100 
μg/ml.  100 μl of WGA+PBS solution was carefully placed on the top of biofilms grown 
on polycarbonate membranes. After incubation for 1 hr at room temperature in darkness, 
excess lectin solution was removed by washing four times with PBS. To stain cells, 100 
μL Syto 9 (Molecular Probes, Eugene, OR) was carefully pipetted onto biofilms and 
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incubated in darkness for 5 minutes. Samples were examined under a LSM 510 laser 
scanning microscope using an excitation wavelength of 595 nm and emission wavelength 
of 615 nm.  
Nucleic Acid Staining and Microscopy 
 Biofilms are cultured as previously described.  Syto 9 (live) and propidium iodide 
(dead) stain from LiveDead Bacterial Viability Kit (Molecular Probes Eugene, OR) were 
used to stain biofilms.  Samples were examined under a LSM 510 laser scanning 
microscope using an excitation wavelength of 405 nm and emission wavelength of 525 
nm.   
Nucleic Acid Degradation and Disruption of Biofilm Architecture 
 Biofilm inoculums were prepared as described above.  Before the inoculation of 
cells onto polycarbonate membrane, DNase I was added to resuspended bacteria to 
concentrations 0, 10, 50, 100 μg/ml. Bacteria + DNase were inoculated onto the 
membranes, and membranes were incubated for 24 hours, followed by staining with 
LiveDead Bacterial Viability Kit (Molecular Probes, Eugene, OR). Samples were 
examined under a LSM 510 laser scanning microscope (Carl Zeiss Inc, NY, USA) using 
an excitation wavelength of 405 nm and emission wavelength of 525 nm. 
Immunodetection 
 Western immunoblotting experiments were performed using matrix protein 
extracts, harvested as explained previously.  Total protein concentration was quantified 
using a BCA Protein Assay Kit (Pierce, Rockford, IL).  Equal protein loads (3μg) were 
electrophoresed on denaturing 6% SDS-PAGE and transferred for 1.5 hours to 0.22 μM 
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nitrocellulose membrane at 330 mA, using Transfer Buffer (0.025M Tris, 0.192M 
Glycine, 20% Methanol) in a Mini Trans-Blot Electrophoretic Transfer Cell (Bio-Rad, 
Hercules, CA).  Membranes were blocked overnight at 4°C, using 5% nonfat condensed 
milk, 0.1% Tween 20 in 1X PBS.  The membrane was probed with 1:1000 dilution 
mouse anti-toxin antibody harvested from C. difficile infected mice [105] for 1 hour in 
5% milk in PBS, 0.1% Tween 20 in PBS at room temperature with shaking.  Membranes 
were washed 3 times with washing buffer (PBS, 0.1% Tween 20) for 10 minutes.  The 
secondary antibody was goat anti-mouse IgG (H+L) HRP conjugate (Jackson Immuno-
Research, West Grove, PA).  Secondary antibodies were incubated for 1hour at RT, then 
washed 3 times with washing buffer and three times with PBS.  Proteins were visualized 
using the SuperSignal West Pico Chemiluminscent Substrate (Pierce, Rockford, IL) 
system, according to the manufacturer’s directions. ImageJ software (NIH, Bethesda, MD 
was used to quantify Western signal.  
Immunofluorescence Microscopy 
 Biofilms were cultured as described above to 3 days old.  Polycarbonate 
membranes were transferred to a Silane coated glass slide (Fisher Scientific, Pittsburgh, 
PA).  Biofilms were blocked with a 5% BSA blocking solution in PBS and was carefully 
added to biofilm and incubated for 1 hour.  Primary antibody incubation was done with 
anti-toxin antibody from C. difficile infected mouse serum [105] in a 1:100 dilution 
overnight at 4°C.  Biofilms were washed 3 times with PBS by carefully pipetting PBS 
onto the membrane, waiting 5 minutes, and then removing the PBS with a pipette and 
filter paper.  The secondary antibody, rat anti-mouse IgG1conjugated to FITC (Catalog # 
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406605, BioLegend, San Diego, CA), was added and the biofilm incubated for 1 hour at 
room temperature.  Then biofilms were washed 3 times with PBS.  Cells were stained 
with 0.05% calcofluor-white for 5 minutes.  Samples were examined under a LSM 510 
laser scanning microscope (Carl Zeiss Inc, NY, USA) using Diode laser (405-430 nm) 
and Argonne laser (488 nm). 
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CHAPTER THREE 
EXPERIMENTAL RESULTS 
Structure and Contents of the C. difficile Biofilm  
 Colony Architecture 
 For an initial characterization, we needed to visualize the actual structure of the C. 
difficile biofilm, including the orientation of cells and the extracellular matrix.  We used 
calcofluor white staining and confocal imaging to visualize a laboratory cultured biofilm, 
and bega to identify the contents of the biofilm, identify stages of growth, and determine 
the structure of the biofilm through the organization of cells, spores, and matrix.  Figure 1 
shows biofilms that we analyzed of three differing stages of 24 hours, 3 days, and 6 days.  
At 24 hours, we saw several small clusters of cells on the outer edges of the macrocolony.  
These colonies contained rod shaped staining particles, consistent with the shape and 
appearance of growing vegetative cells.  At 3 days, the small cell clusters on the edge of 
the macrocolony we saw at 24 hours were no longer present, but we did see cell clusters 
on the interior of the macrocolony.  Instead, 3 day old biofilms contained rod shaped 
vegetative cells, as well as smaller staining particles.  To identify the smaller staining 
particles, we used phase contrast microscopy and saw ovoid shaped spores (Fig 1B).  A 6 
day old biofilm contained very few rod shaped vegetative cells, and contained abundant 
ovoid shaped spores on the inside of the colony.  Small cell clusters containing vegetative 
cells were visible on the outer edges.
27 
 
28 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 1. A) CLSM imaging, with calcofluor, of laboratory-cultured biofilms over 6 days.  
From left to right: Calcofluor stained 1 day (strain BI17), 3 day (BI6) and 6 day (BY1) 
biofilms.  X-Y  (center), X-Z (top), and Y-Z (right side) are shown.  A cell “cluster” is 
evident in the upper right of the left panel.  Rod shaped vegetative cells are evident at 3 
days (middle) and spores (ovoid shaped) are predominant at 6 days (right).  Data is 
representative of all strains analyzed. 
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Figure 1. B) Phase contrast and fluorescent images of a 6 day biofilm (strain BI6).  The 
same field is imaged with calcofluor staining (left) and phase contrast (right).  Circled 
areas emphasize clusters of spores. 
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Extracellular Nucleic Acid  
 In well studied biofilm species, extracellular nucleic acid (eDNA) has been 
demonstrated as a matrix component [106-108].  eDNA has been implicated as a 
necessary component for initial biofilm formation and may be important for the structural 
integrity of the biofilm [106-108].  As a preliminary experiment, we wanted to determine 
whether extracellular DNA was present in the C. difficile biofilm matrix.  We used live-
dead cell staining to identify and locate eDNA in the matrix.  Figure 2 demonstrates both 
live and dead cell material in the biofilm.  Syto-9 staining (shown in green) shows rod 
shaped particles, which are presumably live cells.  Propidium iodide staining (shown in 
red) reveals diffuse staining throughout the entire field, as well as some red cells, which 
is evidence of dead or dying cells. When shown as individual fields, it is evident that 
propidium iodide is space filling in the field (circled areas in Fig 2).  I interpret this as 
evidence for free nucleic acid content present in the matrix.   
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Figure 2. CLSM imaging of a laboratory cultured biofilm using the nucleic acid stains 
Syto-9 and propidium iodide. A. Syto-9 (green) and propidium iodide (red) double 
labeling of a 3-day biofilm (strain BI6).  Syto-9 stains live cells and propidium iodide 
stains dead cell material. B and C shows the same field, without merging the two 
channels, so that the propidium iodide (right) and Syto-9 (left) staining can be seen 
individually. Circled areas indicate space filling extracellular DNA where cells are 
absent. 
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Extracellular Polysaccharides 
 Polysaccharide content is a major component of most biofilms and comprises a 
large part of the EPS.  Biofilm sugars form a thick covering over cells, protecting the 
biofilm cells from physical stress, providing structural strength to the biofilm and evasion 
from host defense and antimicrobial degradation [74, 85].  As a preliminary experiment, 
we first wanted to identify whether polysaccharides were a component of the C. difficile 
biofilm matrix.  We used a phenol sulfuric acid assay to test this possibility [114].  The 
phenol sulfuric acid assay of biofilm matrix extracts showed a slightly yellow color, 
which was darker than the control MQ-H2O and 50 μg/ml galactose standard, but lighter 
in color than the 250 μg/ml galactose sample (Figure 3). The coloration of the biofilm 
matrix extracts did not visually differ between the three biofilm ages (1, 3, and 6 days) 
(Fig 3).  I used this visual comparison to interpret that indeed carbohydrate was present in 
the biofilm matrix. 
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Figure 3.  Phenol sulfuric acid assay comparing the polysaccharide concentration of 
laboratory cultured biofilms to galactose concentrations.  Polysaccharide concentration of  
C. difficile strain BI17 (right) biofilm matrix compared to galactose and water shows the 
polysaccharide concentration does not vary greatly by biofilm maturity, and appears to 
contain between 50 μg/ml and 250 μg/ml polysaccharide. Lanes: 1) MQ-H2O, 2) 50 
μg/ml galactose, 3) 250 μg/ml galactose, 4) 500 μg/ml galactose, 5) 1 day biofilm, 6) 3 
day biofilm, 7) 6 day biofilm.  
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We then sought to identify whether the matrix polysaccharides exhibited any localization 
to particular areas of the biofilm.  We hypothesized that the polysaccharide content would 
potentially vary with sugars being localized to cells and spores, or to the outer edges of 
the biofilm matrix.  To address this hypothesis, we used specific sugar binding lectins and 
the polysaccharide stain calcofluor white along with confocal microscopy to determine 
polysaccharide binding in the biofilm. 
 CLSM imaging with calcofluor white showed rod shaped and ovoid structures, 
shown previously in Figure 1.  I interpret these to be cells and spores, which I confirmed 
with phase contrast microscopy.  The calcofluor staining revealed that cells and spores 
are surrounded by polysaccharide.   
 The fluorescently bound lectins, which bind particular subsets of sugars, 
interestingly revealed variable staining patterns that differ from calcofluor white staining.  
We first tested polysaccharide binding with Concanavalin A (ConA) lectin.  For cellular 
identification, we also used Syto-9 staining.  Syto-9 is a nucleic acid stain that binds 
DNA in live cells, and fluoresces green.  When staining with ConA and Syto-9, cells 
were shown in green (Syto-9) and there was strong red fluorescence (ConA) in between 
cells (Figure 4). No cells were stained red, though there was a small amount of overlap 
with some cells stained yellow.  On the basis of diffuse ConA binding present throughout 
the biofilm, we conclude that the lectin ConA binds the biofilm matrix.   
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Figure 4. CLSM imaging of a laboratory cultured biofilm using the nucleic acid stain 
Syto-9 and the lectin ConA.  A. Syto-9 (green) and ConA (red) double labeling of a 3-day 
biofilm (strain BI6).  ConA stains the apparent cellular debris but, for the most part, not 
the cells.  B and C shows the same field,  without merging the two channels, so that the 
ConA (left) and Syto-9 (right) staining can be seen individually.  
 
 
36 
 
 
When we tested a second lectin, Triticum vulgaris lectin (WGA), we identified yet a 
different pattern of polysaccharide binding. Small areas of high fluorescence showed that 
WGA binding polysaccharide is present in the biofilm (Fig 5), in small rod shaped 
particles, which are presumably cells. WGA appeared to bind only a small subset of cells, 
in an apparently random orientation in the biofilm.  When we compared WGA staining 
using three different concentrations of lectin staining, the red WGA staining appeared to 
increase with increased lectin concentration (Fig 6).  The WGA positively stained cells 
clustered in small areas, or “islands” of the biofilm.  A potential explanation for the 
binding areas might be that WGA stains dead or dying cells, though this speculation is 
unconfirmed by experimental evidence. It is also possible that WGA stains somewhat 
differentiated cells, in which some cells may express WGA-binding matrix while other 
cells do not. 
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Figure 5. CLSM imaging of a laboratory cultured biofilm using the nucleic acid stain 
Syto-9 and the lectin WGA.  A. Syto-9 (green) and WGA (red) double labeling of a 3-day 
biofilm (strain BY1).  WGA stained small areas and some cells. B and C shows the same 
field, without merging the two channels, so that the WGA (right) and Syto-9 (left) 
staining can be seen individually.  
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Figure 6.  CLSM imaging of a laboratory cultures biofilm using the nucleic acid stain 
Syto-9 and the lectin WGA.  Syto-9 (green) and WGA (red) double labeling of a 3-day 
biofilm (strain J9).  WGA stains small bright aggregates which are likely cells, possibly 
dead cells.  From left to right, biofilms cultured with 0 μg/ml WGA (negative control), 10 
μg/ml WGA, 50 μg/ml WGA, 100 μg/ml WGA. 
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Biofilm Matrix Proteins 
 Biofilm matrix proteins are of interest as they may be involved in biofilm 
structure and formation [74].  To visualize the protein composition of the matrix, we 
isolated extracellular matrix from cells and spores using centrifugation and filtration, 
followed by gel electrophoresis of the matrix extract.  Our goal was to identify 
differences in the electrophoretic protein patterns amongst strains.  Perhaps the toxigenic 
strains contained proteins that were distinct from non-toxigenic strains.  Figure 7 shows a 
comparison of the electrophoretic profiles of all seven clinical isolate strains used in this 
study.  We tested 3 non-toxigenic strains, 2 toxigenic but not hypervirulent strains, and 
two hypervirulent BI strains.  We could not determine any noticeable differences in the 
protein electrophoresis between any of the strains, indicating there was not an obvious 
difference in protein electrophoresis between non-toxigenic, toxigenic, or hypervirulent 
strains. 
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Figure 7. SDS-PAGE analysis of the matrix.  5 day biofilms were salt-extracted and 
filtered to remove cells prior to solubilization and electrophoresis.  SDS-PAGE (12%) of 
biofilm matrix extracts (coomassie stained) reveals similar electrophoretic patterns 
between all strains analyzed. Strains, from left to right: BY1, BI6, J9, BI17, CH1, M3, 
K14.  .  
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Once we knew the electrophoretic patterns of matrix proteins were not variable amongst 
individual strains, we next sought to determine if there were particular proteins that were 
distinct in the biofilm matrix when compared to planktonic cell surface proteins.  To 
address this possibility, we visually compared the electrophoretic patterns of biofilm 
matrix with liberated biofilm cell surface proteins.  Figure 8 provides evidence that 
matrix proteins are not merely liberated bifilm cell surface proteins present in the matrix 
due to our matrix extraction process.  It also indicates multiple protein bands that were 
present in the matrix extract and not the cell surface proteins.  We analyzed seven strains, 
and these data are representative of all strains, indicating the analysis shown is not strain 
specific. We chose 4 abundant matrix protein bands for mass spectrometry that were not 
visible in lanes containing cell surface proteins.  We were able to identify eight metabolic 
enzymes present in the biofilm matrix.  Shown in Figure 8, we identified the enzymes 
acetaldehyde/alcohol dehydrogenase, uppermost band; formate-tetrahydrofolate ligase, 
second band from top; acetyl-CoA acetyltransferase, hydroxyisocaproate CoA-
transferase, glutamate dehydrogenase and amino acid aminotransferase, third band from 
top; hydroxybutyryl-CoA dehydrogenase, fructose-bisphosphate aldolase and formate-
tetrahydrofolate ligase, bottom band.  All of these proteins are common metabolic 
enzymes, normally found in the cytoplasm of cells. 
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Figure 8. SDS-PAGE analysis of the matrix. 5 day biofilms were salt-extracted and 
filtered to remove cells prior to solubilization and electrophoresis.  SDS-PAGE (12%) of 
extracts from toxigenic strain J9 (Coomassie stained). Lanes: 1) planktonic cell surface 
extraction, 2) matrix extract.  Arrowheads on the right indicate bands which were excised 
for MS.   
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Cellular lysis and dead cell material as a matrix component 
 Knowing then that matrix proteins are not simply cell surface proteins, and that 
cytoplasmic proteins are present in the matrix, we asked how such proteins are released 
into the matrix.  It is well documented that a main protein component of the B. subtilis 
biofilm, TasA, is secreted into the matrix [103, 109].  Secretion may be involved in 
matrix protein delivery, as well as the possibility for cell lysis liberating cytoplasmic 
proteins.  We used SDS-PAGE to compare the electrophoretic patterns of biofilm matrix 
proteins with whole biofilm cell lysates.  Figure 9 reveals that the electrophoretic profiles 
of matrix proteins and whole biofilm cell lysates are very similar, with no noticeable 
differences between the protein patterns.  We analyzed seven strains: BI6, BI17, BY1, 
CH1, M3, K14, and J9, with consistent results indicating the evidence is general for all 
strains.  I interpret this to mean that a major component of biofilm matrix proteins come 
from lysed cell material, and is released cytoplasmic protein that has been liberated into 
the matrix.   
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Figure 9. SDS-PAGE analysis of the matrix. 5 day biofilms were salt-extracted and 
filtered to remove cells prior to solubilization and electrophoresis.  A. SDS-PAGE (12%) 
of extracts from toxigenic stain BI17 (Coomassie stained).  Lanes: 1) matrix extract, 2) 
biofilm cell lysate.   
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Structural Role of Extracellular DNA and Biofilm Formation 
 Extracellular DNA is a necessary component in initial biofilm formation 
 Extracellular DNA has been shown to be a crucial component in initial biofilm 
formation of multiple bacterial species [106, 107].  eDNA is involved in colony 
architecture and adhesion of cells to each other, as well as attachment to surfaces during 
colony formation.  Previously, we identified eDNA in the laboratory cultured C. difficile 
biofilm, and next wanted to identify the role of eDNA in biofilm structure.  The enzyme 
DNase degrades extracellular DNA and causes disruption in the biofilm architecture of 
several species [107].  By removing extracellular DNA, I was able to determine if eDNA 
is important to the structural integrity of the biofilm, and if the absence of eDNA disrupts 
the normal architecture of a biofilm. 
 We cultured biofilms with DNase, adding the enzyme at the time of inoculation.  
We then allowed the biofilms to grow for 24 hours and followed with LiveDead cell 
staining and confocal microscopy.    Figure 10 shows biofilms grown with DNase at 24 
hours old.  The biofilms exhibited varying degrees of disruption when compared to a 
normal laboratory cultured biofilm.  Disruption of the biofilm was characterized as 
decreased live cell density, and the presence of “holes” that were free of both propidium 
iodide and Syto 9 staining.  We defined cellular density as the degree of how closely cells 
were packed together.  The propidium iodide staining (red) was decreased, and the Syto-9 
staining (green), which stains live cells, appeared less dense than the control biofilm (Fig 
10A).  I noticed “holes” present in the DNase treated biofilm, where no staining was 
present at all.  The three concentrations of DNase also showed varying degrees of 
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disruption.  When I inoculated biofilms with10 μg/ml DNase, live cell density was 
decreased, and some small “holes” free of staining were present (Fig 10B).  For 50 μg/ml 
biofilms, the live cell density was decreased even further, and I saw even larger holes in 
the biofilm (Fig 10C).  At 100 μg/ml, I observed even greater disruption in the biofilm, 
with large holes present and the least densely packed cells (Fig 10D) compared to a 
standard biofilm (Fig 10A).  However, over 6 repetitions, the amount of disruption seen 
was inconsistent.  I was unable to produce consistent disruption in the biofilm.  The three 
concentrations of DNase also showed varying degrees of disruption.  Using three 
concentrations of DNase (10 μg/ml, 50 μg/ml, and 100 μg/ml), I saw concentration-
dependent disruption in 2 trials.  In 4 additional trials, disruption was either not seen at all 
(Fig 10E-H), or one biofilm would exhibit disruption while the other biofilms tested 
appeared to be unaffected by DNase treatment.  Disruption also varied at differing 
locations in the biofilm.  The amount of disruption at the outer edges of the biofilm was 
greatest, with many more holes visible on the outer edge of the biofilm than in the center 
of the biofilm.   
 
 
47 
 
 
 
 
Figure 10.  CLSM imaging of DNase treated laboratory cultured biofilms using the 
nucleic acid stains Syto-9 and propidium iodide.  Syto-9 (green) and propidium iodide 
(red) double labeling of 24 hour biofilms (strain J9).  Syto-9 stains live cells and 
propidium iodide stains dead cell material. From left to right: A,E) 0 μg/ml DNase, B,F) 
10 μg/ml, C,G) 50 μg/ml, D,H) 100 μg/ml.  Disruption is evident in a concentration 
dependent manner compared to negative controls, but the effect of DNase is inconsistent.  
Images E-H represents unsuccessful trials where DNase did not produce biofilm 
disruption. 
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 The absence of extracellular DNA alters cellular orientation in biofilm 
architecture 
 The effect of DNase on initial biofilm architecture appears to create a disruptive 
effect, albeit inconsistently.  But we wanted to determine the effects of DNase in older 
biofilms.  We again cultured biofilms with DNase, but allowed the biofilms to grow for 
48 hours before staining and imaging.  When I imaged 48 hour biofilms, I saw no “holes” 
present and no visible decrease in live cell density when compared to the control biofilm 
grown without DNase (Fig 11).  However, there was an interesting effect in which the 
DNase treated biofilms appeared to show less cellular organization than the control.  As 
shown in the control (Fig 11A), normally cultured biofilms exhibited some measure of 
organization, where cells were stacked in a linear fashion.  We consistently saw this 
stacking in all regularly cultured biofilms.  Compare this to the DNase treated biofilm, 
the biofilm appeared to be disorganized, with cells facing in all directions and no 
consistent pattern was visible (Fig 11B).  These results are representative of only one 
experimental attempt.     
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Figure 11. CLSM imaging of 48 hour DNase treated laboratory cultured biofilms using 
the nucleic acid stains Syto-9 and propidium iodide.  Syto-9 (green) and propidium 
iodide(red) double labeling of 48 hour biofilms (strain BI6).  Syto-9 stains live cells and 
propidium iodide stains dead cell material. Left: biofilm cultured with 0 μg/ml DNase 
(negative control).  Right: biofilm cultured with 100μg/ml DNase.   
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Biofilm Toxins 
 Toxin in the Biofilm Matrix 
 Toxigenic Clostridium difficile produces two large toxins, A and B, which are 
primarily responsible for CDI.  The immune system of the host recognizes and creates an 
immune response to both toxins, and this antibody response is a strong indicator of 
current or previous infection [36, 110, 111].  We wanted to identify toxin in the 
laboratory cultured biofilm as a preliminary experiment to verify that toxin was present in 
the biofilm.  We used a Western immunoblot analysis with anti-toxin antiserum 
C.difficile infected mice [105] and biofilm matrix proteins which were extracted as 
described above, shown in Figure 12.  From the Western blot, I saw reactive bands of 
high molecular weight (around 300 kDa), present in only toxigenic strains.  No reactivity 
was seen in non-toxigenic strains.  Also, as this serum has previously been demonstrated 
to contain anti-toxin antibodies by Pehga Johnston in the Knight Lab, I interpret these 
observations as evidence that toxin is present in the biofilm.  
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Figure 12. Western blot analysis of the matrix.  SDS-PAGE (6%) of matrix extract and 
western blot analysis using a mouse anti-toxin antiserum.  Lanes 1) non-toxigenic strain 
CH1, 2) non-toxigenic strain BY1, 3) toxigenic strain K14, 4) toxigenic strain BI6.  There 
is an empty lane between 2 and 3.  
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Survey of multiple CD strains reveal variation in toxin levels 
  The amount of toxin present in a given biofilm matrix may identify particular C. 
difficile strains with potential to cause more severe disease with higher toxin production. 
There is evidence of differences in toxin production in toxigenic strains seen in liquid 
culture [112], but it is possible that a biofilm may be more representative of in vivo 
colonization and disease.  Therefore, we wanted to compare the levels of toxin in the 
biofilm amongst multiple strains.  We cultured biofilms for 5 days, using four toxigenic 
strains (BI17, BI6, K14, J9) and non-toxigenic BY1 as a negative control.  The Western 
blot identified signals at around 300 kDa, indicating toxin was present in all toxigenic 
strains (Figure 13A).  No signal was evident in non-toxigenic strain BY1 or using pre-
immune serum.  Amongst toxigenic strains, the intensity of signal is approximately equal.  
We used ImageJ technology (NIH, Bethesda, MD) to measure the density of the Western 
signal so that we could quantitatively compare each blot.  This led us to interpret that the 
toxin levels in 5 day biofilms amongst these four toxigenic strains were at approximately 
equal concentrations.   
Seeing little difference in toxin levels at 5 days old, we next compared toxin levels in 
younger biofilms.  A 5 day biofilm consists of mostly spores, so we chose a 3 day biofilm 
where the cellular population consists of both vegetative cells and spores.  In Figure 13B 
we see that the two hypervirulent strains BI6 and BI17 have a two fold increase in toxin 
when compared to the toxigenic, but not hypervirulent strains J9 and K14.  These data are 
representative of one repetition.  
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Variation in biofilm toxin over time 
 We next investigated the toxin content in biofilms of differing maturity.  As a 
biofilm ages, the mass increases as cells divide and extracellular matrix increases with an 
increase in cell lysis.  It is reasonable that the amount of toxin may increase in the biofilm 
with the increase in protein.  Alternatively, the amount of toxin may correlate with the 
population of vegetative cells compared to spores in the biofilm.  We may expect to see 
higher levels of toxin in younger biofilms, which consist primarily of vegetative cells.  As 
a C. difficile biofilm ages, the population of vegetative cells declines, and the 
concentration of spores increases.  Vegetative cells produce toxin, while spores do not.  
Therefore, the amount of toxin in a biofilm may correlate with the amount of vegetative 
cells, and sporulation may decrease toxin levels in the biofilm matrix.   
The Western blot comparing biofilms from strain BI6 at 1, 3, 5, and 6 days old indicated 
that the level of toxin increases in biofilms over time (Fig 14).  Each lane was loaded 
with the same amount of protein (1.16 μg).  Therefore, the increase in toxin we saw in 
biofilms over time was independent of an increase in the total protein concentration we 
expected from an increase in biofilm size.  The proportion of toxin to overall protein 
concentration was increasing with time.  Also, we saw toxin production well into the time 
of sporulation, which begins at 3 days, and at 6 days the biofilm was almost entirely 
composed of spores.  A potential explanation for this may be due to the increase of total 
cell mass as a biofilm ages.  Older biofilms have undergone extensive cell division, 
possibly leading to more toxin producers in an older biofilm, which would potentially 
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account for the increased toxin levels despite high levels of sporulation. These data are 
representative of one repetition. 
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Figure 14.  Timecourse western blot analysis of toxin levels in the matrix.  SDS-PAGE 
(6%) of toxigenic strain BI6 matrix extract and western blot analysis using a mouse anti-
toxin antiserum.   
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Toxin localization in the biofilm matrix   
 The accumulation of toxin in the biofilm, and possible localization to specific 
areas of the biofilm, may facilitate CDI.  Different locations for toxin accumulation in the 
biofilm may indicate the method of toxin delivery to the host.  The potential funneling of 
toxin to the biofilm-host epithelial interface could enable toxin to create the most 
epithelial damage.  Or, if toxin is located near the edges of the biofilm matrix, pieces of 
biofilm matrix may break off to deliver toxin to the host.  Finally, toxin may be cell 
associated, and cells may actually need to migrate to the host mucosal surface to 
introduce toxin and create epithelial damage.   We used immunofluorescence to try to 
visualize the location of toxin in the biofilm matrix.  We imaged 3 day old biofilms of 
three different strains, toxigenic BI17 and J9, and non-toxigenic BY1 as a negative 
control.  As shown in Figure 15, in both toxigenic strains, we saw small bright aggregates 
of fluorescence that were absent in all negative controls.  Cells and spores were stained in 
blue from the polysaccharide specific stain calcofluor white.  The small punctate green 
aggregates were not cell or spore associated, and no overlap in fluorescence was seen 
between the green aggregates and blue cells or spores in the merged image.  Using an 
anti-toxin antibody, which complexes with a goat anti-mouse FITC conjugated secondary 
antibody, we are confident that the bright green aggregates were toxin present in the 
biofilm matrix.  It appeared that toxin molecules associated to form the aggregates seen 
in the matrix.  Using a naïve mouse pre-immune serum, we saw that there was some cell 
associated background binding.  This is also present in non-toxigenic strain BY1 (Figure 
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16).  The toxin aggregates were absent from all negative controls.  These data are 
representative of one repetition. 
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CHAPTER FOUR 
DISCUSSION 
Cellular fate in biofilm matrix production 
 It has been well documented that biofilms are composed of cells and matrix, with 
the matrix frequently consisting of polysaccharide, protein, and nucleic acid [74].  In our 
preliminary experiments, we have shown that the C. difficile biofilm consists of all three 
traditional matrix components.  Interestingly, we showed that the protein electrophoresis 
of matrix proteins was very similar in appearance to a protein electrophoresis from a 
biofilm cell lysate.  When we excised 4 abundant protein bands for mass spectrometry, 
we identified 8 metabolic enzymes present, which are normally in the cytoplasm of cells.  
Therefore, it appears that released cytoplasmic contents are a major part of the C. difficile 
biofilm matrix.  Cellular lysis has been indicated as an important contributor to biofilm 
development.  The 2007 review by Kenneth Bayles describes the role and regulation of 
cell death in S. aureus biofilms.  In this review, Bayles indicates that biofilm 
development is facilitated by a highly regulated gene network that selectively targets 
biofilm cells for apoptosis.  The resulting cellular debris, including nucleic acid, serves as 
the “glue” to hold biofilm cells together during initial biofilm development [113].  The 
role of cell death has also been surveyed in Gram-positive B. subtilis.  Cannibalism in the 
biofilm is a well documented trait of selectively differentiated cells.   Differentiated cells 
act as cannibals, but they also play a second role as matrix producers.  Cannibal cells 
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commit fratricide to neighboring cells, releasing nutrients to be used by the 
cannibals/matrix producers.  Matrix production is thought to be a metabolically taxing 
event, therefore the cannibal cells utilize nutrients from neighbors to fuel matrix 
production and delay sporulation due to nutrient depletion [102]. 
 The role of lysed cellular contents in B. subtilis biofilms has been indicated as a 
nutrient provider, not as an actual matrix component.  The B. subtilis biofilm consists of 
two major secreted matrix components; the structural protein TasA and the extracellular 
polysaccharides EPS [103].  While B. subtilis is phylogenetically very distinct from C. 
difficile, B. subtilis is the best studied Gram-positive biofilm and a model organism upon 
which we base several experimental questions.  In our studies, we did not find any major 
protein which would serve as a structural base for the C. difficile biofilm; instead we 
found lysed cell material to be a major component.  This leads us to speculate about the 
cell fate and differentiation in C. difficile biofilms.  Cellular differentiation has been 
extensively studied in B. subtilis biofilms and it implicates several different populations.  
Initially the biofilm consists of mostly motile cells.   At about 24 hours of growth, many 
cells lose their motility and differentiate into matrix producers/cannibals, miners, 
surfactin producers, and later in biofilm growth, sporulating cells [78, 104].  While 
cellular differentiation in C. difficile biofilms is not known, we can speculate about two 
potential fates of C. difficile cells in biofilm growth.  Assuming that C. difficile biofilms 
do not contain a major structural protein like TasA, and cell lysis is the major contributor 
to extracellular matrix production, we can hypothesize that C. difficile biofilm cells are 
initially undifferentiated and later differentiate into spore producers, or undergo apoptosis 
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and lyse to provide matrix material.  This is further supported by evidence that the 
structural protein TasA is not encoded in the C. difficile genome. We do not currently 
have evidene of matricx production in cells.  Rather, we have identified cellular lysis as a 
major event that contributes to the C. difficile biofilm matrix.  It is very plausible that 
vegetative cells produce matrix prior to lysis and sporulation.  We can propose a model 
for cellular differentiation in a C. difficile biofilm that is distinct from B. subtilis and 
serves as an alternative model for Gram-positive biofilms (Fig 17).   It is an intriguing 
idea to determine the cell fate of C. difficile cells during biofilm growth, and with greater 
study those biofilm developmental events will likely become clearer.   
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Figure 17.  Model for cellular differentiation in C. difficile biofilms.  Motile cells 
aggregate and are initially undifferentiated.  Cells differentiate into matrix producers and 
secrete toxin, then eventually sporulate or lyse to contribute to the matrix.  Sporulation 
produces a spore, and the lysed mother cell becomes part of the extracellular matrix. 
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Contribution of Extracellular DNA to Biofilm Formation and Architecture 
 The biofilm disruption I observed indicates that eDNA is potentially an important 
component to biofilm structure and is necessary for proper biofilm formation.  The 
importance of eDNA to biofilm formation has been well documented in other biofilm 
species, showing results that are consistent with my findings.  DNase treatment seems to 
have the greatest effect early in biofilm development [106].  24 hour biofilms showed 
considerably greater disruption than 48 hour biofilms, indicating that eDNA may not be 
as crucial to the structure of more mature biofilms.  This observation is consistent with 
Whitchurch et al  which suggests that as biofilms mature, the extracellular DNA becomes 
less important to biofilm integrity, as polysaccharides and proteins in the matrix support 
the biofilm structure [106].  The dense packing of cells was decreased with increasing 
DNase concentration, leading to the interpretation that extracellular nucleic acid is 
important for adhesion of cells to one another.  Also, the “holes” that I observed in 
DNase treated biofilms may show that eDNA is also important for biofilm adhesion to 
surfaces. We were unable to create consistent disruptive effects in the biofilm through the 
removal of extracellular DNA with DNase.  Through 6 experimental attempts, disruption 
only occurred in 4 trials.  Additionally, the concentration dependent disruption we 
observed in the first experimental attempt could not be recreated through multiple 
repetitions.  I did see disruption in additional attempts, but could not repeat concentration 
dependent disruption.  The severity of disruption was not consistent with each trial; 
therefore, we are unable to make any conclusive remarks about the effects of increased 
concentrations of DNase on biofilm development or organization.  There were several 
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small variables in the experiment that make this experiment difficult to reproduce.  The 
first potential variable is the time of inoculation.  When our lab inoculates culture for 
biofilm growth, we attempt to achieve a consistent optical density of overnight culture, 
though this is not always the case.  Due to small changes in the culture timing, the time of 
inoculation in regards to the density of culture may vary.  For most experiments, this is 
not an issue.  But we do expect the differences in eDNA to affect initial attachment of 
cells to the surface.  As attachment is the initial step in biofilm formation, precise timing 
may very well determine the effect of DNase on initial attachment.  The second variable 
to consider is the action of DNase.  While the enzyme we use is taken from the same 
stock for each experiment, the action of the enzyme may fluctuate too greatly to produce 
consistent results.  What we have determined from multiple repetitions is that 
extracellular DNA is important for initial biofilm formation, and the absence of eDNA 
disrupts the biofilm architecture.  The extent of that disruption is unclear.  Our lab will 
continue to explore the role matrix eDNA in biofilm formation with additional evaluation 
of the experimental design. 
Toxin Production in Biofilms of Hypervirulent Strains of C. difficile 
 Despite great advances in the molecular study of C. difficile, the molecular 
mechanism underlying the emergence of hypervirulent strains is still far from understood.  
Specifically, the amount of toxin and onset of toxin production have been studied 
previously with several conflicting results.  Most recently, the laboratory of Dr. Dale 
Gerding determined differences in toxin production for several hypervirulent strains and 
toxigenic, but not hypervirulent, strains.  Through this work it was determined that the 
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hypervirulent strains tested did not produce greater amount of toxin than non-
hypervirulent strains tested in liquid culture [112].  Through my studies, we have only 
experimented with two HV strains, BI17 and BI6.  These two strains in no way represent 
the entirety of the hypervirulent strains, making strain selection in future studies with 
regard to hypervirulent C. difficile biofilms of critical importance.  The difference in 
growth and toxin production in biofilms rather than liquid culture could potentially be 
more representative of toxin production during infection in the host.  Our data indicates 
toxin production in BI strains is higher in younger biofilms than non-hypervirulent strains 
by a two-fold increase.  This suggests that the hypervirulent strains we tested produce 
toxin at a higher rate earlier in biofilm growth.  Experiments to demonstrate and validate 
this observation are ongoing to determine when toxin is being produced at the earliest 
time during biofilm development.  It is likely though that hypervirulence cannot be 
attributed simply to differences in toxin production amongst strains.  For example, strain 
VPI10463, which is the highest known toxin producer, is not hypervirulent and is not 
commonly found in clinical patient isolates.  VPI10463 has not become an epidemic 
strain, providing evidence that toxin production cannot be the sole factor in determining 
hypervirulence.  However, experiments including toxin quantification are critical in 
defining the C. difficile biofilm as a virulence factor for CDI. 
Toxin Localization in CD Biofilms  
 A potential explanation for the appearance of toxin aggregates in the matrix may 
be due to cellular debris, also present in the matrix.  Toxin may accumulate around a 
piece of cell membrane, or around nucleic acid in the matrix.  As we have seen that 
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cellular lysis is a common event in C. difficile biofilm growth (shown previously), that 
contributes to the formation of the matrix, it is plausible that toxin may aggregate around 
a piece of debris in the matrix.  Toxin was diffuse throughout the matrix, with high 
concentrations located around small aggregates in the matrix, which are potentially 
cellular debris.  It is possible therefore to speculate about the mechanism of toxin 
delivery to the host, as well as some experimental limitations from our 
immunofluorescence microscopy.  The growth of laboratory cultured biofilms is 
accomplished on a solid polycarbonate membrane placed on top of agar medium.  While 
it is an efficient method for in vitro biofilm growth, there are certainly events in vivo that 
are not represented by our model.  The location of toxin would be best studied in an in 
vivo model where the surface association of biofilm to host mucosal surfaces would be 
more representative of biofilm growth during CDI.   
 The dispersal of motile bacteria in biofilm growth has been well documented in 
several species.  Sloughing dispersal liberates large pieces of biofilm late in biofilm 
growth, while erosion of the biofilm involves biofilms breaking off in small pieces and 
being released over the development of the biofilm [81, 82].  The B. subtilis biofilm 
likely undergoes both methods of dispersal, and has been shown to completely 
disassemble with the addition of D-amino acids.  While these observations have only 
been discussed in the context of motile cell release from the biofilm, it is intriguing to 
speculate about the role of dispersion in toxin delivery.  It is possible that in the C. 
difficile biofilm, toxin is delivered to new parts of the gut when dispersal occurs.  Pieces 
of the biofilm could break off, liberating cells and toxin to new areas of the gut.  Then, as 
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the released bacteria colonize new tissue, toxin is already available and able to initiate 
epithelial damage before an immune response could be activated, and prior to the 
production of toxin from the new colony.   
Clinical Relevance of Biofilm Characterization 
 There are several mechanisms by which C. difficile biofilms could contribute to 
CDI.  The biofilm may contribute by resisting antimicrobial drugs and host defense 
mechanisms; by facilitating attachment of C. difficile to appropriate locations in the 
colon; by accumulating toxin and directing it to host tissues; and by harboring a reservoir 
of dormant spores that could facilitate relapsing disease.   My characterization of the 
biofilm will provide a foundation for developing novel therapeutics, including vaccines 
and probiotics, which rely on knowledge of the host-pathogen interaction.   Biofilms play 
a critical role in pathogenesis.   Biofilms allow persistence in the host, and can facilitate 
relapsing infection.  We will use what we have learned about the biofilm, and will 
analyze those properties that could influence CDI and treatment of the disease.  Our 
preliminary in vitro characterization provides a foundation for in vivo studies, which 
could significantly accelerate development of novel treatments.  In future work, we will 
use these data to further clarify our understanding of CDI pathophysiology.  We will 
alsomore deeply analyze the molecular composition of the biofilm.   We will focus 
especially on identifying targets for novel therapeutics, and the design of probiotic 
treatments. 
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Future Directions 
 Disruption of biofilm architecture with the addition of DNase 
  We have documented several stages in biofilm development, yet we do not 
know the molecular mechanisms of biofilm growth.  Attachment of cells to a surface is 
an early step in biofilm growth and the creation of a microcolony.  Certainly, in the 
course of CDI, attachment of bacteria to host mucosa is a critical step in pathogenesis.  
We need to determine the contribution of extracellular DNA in biofilm formation.  As 
discussed previously, we will need to eliminate small variances in the inoculation of 
polycarbonate membranes to initiate biofilm development, as that could affect the initial 
formation of the biofilm.  There are several additional experiments we would like to 
perform to determine the contribution of eDNA to biofilm formation.  This includes the 
addition of DNase to degrade eDNA at varying timepoints.  Our previous experiments 
involved the addition of DNase once during inoculation and imaging the biofilms at 24 
hours and 48 hours of growth. 24 hours may be too late to visualize the important 
changes in biofilm attachment that could be affected by the absence of eDNA.  We also 
will continually add DNase to visualize the disruptive effects of DNase over time.  In our 
previous experiments, we likely lost the effect of DNase long before confocal 
microscopy.  Also, cellular lysis continues with biofilm growth, and cellular lysis 
supplies the matrix with additional eDNA.  If we can continually add DNase several 
times during biofilm development, we would likely see greater disruption and learn more 
about the role of eDNA in biofilm development. 
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 Toxin Production and Localization in CD Biofilms  
 We have completed some preliminary experiments to determine the 
concentrations and location of toxin in the biofilm with a survey of 4 strains.  Previous 
work by Michelle Merrigan demonstrated the absence of significant differences in toxin 
levels in liquid culture, indicating that differences in toxin levels cannot determine 
hypervirulence [112].  I agree that hypervirulence is likely due to many complex factors 
that have not yet been determined.  Our preliminary results indicate that toxin levels in 
the hypervirulent BI strains are two fold higher than non-HV strains.  Repetition and 
toxin quantification in younger biofilms will determine if this is a consistent result.  
Additionally, quantifying toxin in more strains will determine if the differences in the 
toxin levels that we see are due to strain variation or a true difference between HV and 
non-HV strains.  Finally, we would like to identify the location of toxin in vivo rather 
than through a laboratory cultured biofilm.  The delivery of toxin to the gut mucosal 
surfaces is an important step in the pathogenesis of CDI.  We would like to determine 
how the biofilm contributes to this critical step, and subsequently may learn about 
dispersal in the C. difficile biofilm.  
 Immune Response to Biofilm Proteins 
 Through Western blot analysis we were able to identify toxin in the biofilm.  We 
also did not observe any antibody binding to other biofilm matrix proteins other than 
toxin.  This indicates that there was not a systemic immune response to matrix proteins 
other than toxin, as the IgG antibodies from C. difficile mice indicate only systemic 
immunity.  However, there should not necessarily be a systemic response to biofilm 
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proteins.  We would like to use mucosal antibodies from several mammalian sources to 
characterize the immune response to C. difficile biofilms, including hamsters and human 
patients.  The effect of C. difficile infection has been well studied in hamsters, and the 
hamster model is used by our collaborators in Dr. Dale Gerding’s lab.  The best mucosal 
antibody to test would be from human patients who have experienced CDI.  Determining 
antigenic proteins in C. difficile biofilms could eventually lead to novel therapeutics and 
improved treatment of CDI.   
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